Literature DB >> 32219718

Hyperprolactinemia and bone.

Luigi di Filippo1, Mauro Doga1, Eugenia Resmini2, Andrea Giustina3.   

Abstract

Prolactin (PRL) has direct and indirect effects on bone metabolism. Experimental studies showed that in the presence of high PRL levels bone resorption was increased as well as bone formation was suppressed. Increased PRL levels in humans caused a reduction in sex hormone levels which turn may have detrimental effects on bone. Patients with hyperprolactinemia did have often decreased bone mineral density as well as an increased risk of fractures. Since PRL control may be relevant to bone health it is a clinical open issue the inclusion of skeletal health in future guidelines as indication to proactive screening, prevention and treatment particularly in high risk patients such as hyperprolactinemic women after menopause and patients with drug induced hyperprolactinemia.

Entities:  

Keywords:  Antipsychotic drugs; Bone density; Bone metabolism; Hyperprolactinemia; Osteoporosis; Prolactin; Vertebral fractures

Mesh:

Substances:

Year:  2020        PMID: 32219718     DOI: 10.1007/s11102-020-01041-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  90 in total

Review 1.  Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D.

Authors:  Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley
Journal:  Br J Clin Pharmacol       Date:  2018-07-17       Impact factor: 4.335

Review 2.  Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice.

Authors:  Isabella Pacchiarotti; Andrea Murru; Georgios D Kotzalidis; C Mar Bonnin; Lorenzo Mazzarini; Francesc Colom; Eduard Vieta
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-14       Impact factor: 4.600

Review 3.  Adverse effects of antipsychotic medications.

Authors:  John Muench; Ann M Hamer
Journal:  Am Fam Physician       Date:  2010-03-01       Impact factor: 3.292

Review 4.  Primary empty sella: Why and when to investigate hypothalamic-pituitary function.

Authors:  A Giustina; G Aimaretti; M Bondanelli; F Buzi; S Cannavò; S Cirillo; A Colao; L De Marinis; D Ferone; M Gasperi; S Grottoli; T Porcelli; E Ghigo; E degli Uberti
Journal:  J Endocrinol Invest       Date:  2010-03-05       Impact factor: 4.256

5.  Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome.

Authors:  Anna Maria Formenti; Mauro Doga; Stefano Frara; Marco Ritelli; Marina Colombi; Giuseppe Banfi; Andrea Giustina
Journal:  Endocrine       Date:  2018-12-15       Impact factor: 3.633

6.  The effect of pregnancy on bone density and bone turnover.

Authors:  K E Naylor; P Iqbal; C Fledelius; R B Fraser; R Eastell
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

7.  Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.

Authors:  Gherardo Mazziotti; Mauro Doga; Stefano Frara; Filippo Maffezzoni; Teresa Porcelli; Luigi Cerri; Roberto Maroldi; Andrea Giustina
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 8.  Pituitary Diseases and Bone.

Authors:  Gherardo Mazziotti; Stefano Frara; Andrea Giustina
Journal:  Endocr Rev       Date:  2018-08-01       Impact factor: 19.871

9.  Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.

Authors:  Christina S Kalkavoura; Ioannis Michopoulos; Periklis Arvanitakis; Pitsa Theodoropoulou; Konstantina Dimopoulou; Errikos Tzebelikos; Lefteris Lykouras
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-08       Impact factor: 3.157

10.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

View more
  2 in total

1.  Paeoniflorin Ameliorates Hyperprolactinemia-Induced Inhibition of Osteoblastogenesis by Suppressing the NF-κB Signaling Pathway.

Authors:  Xiaohong Sun; Keda Zhu; Chengcheng Feng; Jie Zhu; Shuangshuang Chen; Wenkai Tang; Zhifang Wang; Long Xiao; Hong Li; Dechun Geng; Zhirong Wang
Journal:  Int J Endocrinol       Date:  2022-04-15       Impact factor: 2.803

2.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.